Drug intelligence / Profile preview

TAK-850

Development stage: Discontinued
Lead developer: Takeda
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

TAK-850 is a quadrivalent influenza vaccine candidate that was developed by Takeda for the prevention of infections caused by influenza virus subtypes A and B. It was designed to be administered as a single subcutaneous injection and evaluated in clinical trials for its safety and immunogenicity compared to standard influenza hemagglutinin (HA) vaccines. The development of TAK-850 has been discontinued[1][2][3][4].

Targets

BCR-HIV-Env (HIV-1 envelope-specific B-cell receptor)TCR (T cell antigen receptor complex)

Beyond the preview

Go deeper on TAK-850.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAK-850.

Explore the full profile